期刊文献+

骨髓间充质干细胞对实验性自身免疫性重症肌无力大鼠的治疗作用 被引量:6

The effect of bone marrow stem cells on the treatment of experimental autoimmune myasthenia gravis rat
下载PDF
导出
摘要 目的探讨骨髓间充质干细胞对实验性自身免疫性重症肌无力大鼠模型的治疗作用及其可能机制。方法全骨髓贴壁筛选法分离培养Lewis大鼠骨髓间充质干细胞,流式细胞术检测其表面分子CD34、CD44的表达。经Lewis大鼠尾静脉注射经体外培养至第3代的骨髓间充质干细胞,7d后腹腔注射抗乙酰胆碱受体单克隆抗体(mAb35)建立实验性自身免疫性重症肌无力动物模型,按照Lennon评分标准进行临床症状评分、Western blotting法检测肌肉组织中乙酰胆碱受体蛋白表达、流式细胞术检测外周血CD4+CD25+T细胞比率、酶联免疫吸附试验检测血清转化生长因子-β、干扰素-γ和IL-4表达变化。结果与生理盐水对照组相比,注射骨髓间充质干细胞的实验性自身免疫性重症肌无力大鼠模型临床评分降低(t=8.062,P=0.000),乙酰胆碱受体α蛋白表达水平升高(t=8.092,P=0.000);同时血清转化生长因子-β表达水平升高(t=9.859,P=0.000),干扰素-γ(t=9.040,P=0.000)和IL-4(t=3.320,P=0.004)表达水平降低,两组之间差异均有统计学意义(P<0.05)。结论骨髓间充质干细胞能够显著减轻实验性自身免疫性重症肌无力大鼠模型临床症状,减少乙酰胆碱受体缺失。其作用机制可能与分泌免疫抑制性细胞因子转化生长因子-β上调CD4+CD25+调节性T细胞表达水平,以及抑制炎性促进因子干扰素-γ和IL-4的分泌有关。 Objective To investigate the effect of bone marrow stem cells (BMSCs) on the treatment of experimental autoimmune myasthenia gravis (EAMG) and the possible pathogenesis. Methods BMSCs were obtained from Lewis rat bone marrow selected by cell attachment, cultured and proliferated in vitro. The expression of surface molecules of CD34 and CD44 was analyzed by flow cytometry. The Lewis rats were divided randomly into group A and group B. The rats in group A were transplanted with the third passage BMSCs, and the rats in group B were injected with physiological saline. Seven days after injection, the rat model of EAMG was established by injecting mAb35 to rats in both groups. Clinical signs and symptoms were assessed with Lennon score. Western blotting method was used to determine the expression of acetylcholine receptor (AChR) protein. The CD4+CD25+ Treg cell ratio was analyzed by flow eytometry. Plasma TGF-β, IFN-γ and IL-4 expressions were detected by ELISA. Results The clinical scores of rats treated with BMSCs were significantly lower than those untreated (t = 8.062, P = 0.000). In comparison with group B, the expression levels of AChR protein (t = 8.092, P = 0.000) and TGF-β (t = 9.859, P = 0.000) in group A were all higher, while IFN-γ (t = 9.040, P = 0.000) and IL-4 (t = 3.320, P = 0.004) were all lower in group A. Conclusion Transplantation with BMSCs can relieve the clinical syndrome of EAMG and reduce the lost of AChR by promoting the level of TGF-β, up regulating the expression of CD4+CD25+ Treg cell ratio, and suppressing IFN-3, and IL-4.
出处 《中国现代神经疾病杂志》 CAS 2012年第2期161-165,共5页 Chinese Journal of Contemporary Neurology and Neurosurgery
基金 浙江省科技厅基金资助项目(项目编号:2006C33008)~~
关键词 重症肌无力 自身免疫性 实验 间质干细胞移植 印迹法 蛋白质 骨髓移植 流式细胞术 Myasthenia gravis, autoimmune, experimental Mesenchymal stem celltransplantation Blotting, western Bone marrow transplantation Flow cytometry
  • 引文网络
  • 相关文献

参考文献15

  • 1Meriggioli MN,Sanders DB. Autoimmune myasthenia gravis:emerging clinical and biological heterogeneity[J].Lancet Neurology,2009.475-490.doi:10.1016/S1474-4422(09)70063-8.
  • 2Chanda D,Isayeva T,Kumar S. Therapeutic potential of adult bone marrow-derived mesenehymal stem cells in prostate cancer bone metastasis[J].Clinical Cancer Research,2009.7175-7185.doi:10.1158/1078-0432.CCR-09-1938.
  • 3Nasef A,Ashammakhi N,Fouillard L. Immunomodulatory effect of mesenchymal stromal cells:possible mechanisms[J].Regen Med,2008.531-546.doi:10.2217/17460751.3.4.531.
  • 4Gomez AM,Vrolix K,Martínez-Martínez P. Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis[J].Journal of Immunology,2011.2503-2513.doi:10.4049/jimmunol.1002539.
  • 5Luo J,Taylor P,Losen M. Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies,nicotinic acetylcholine receptor conformation maturation,and agonist sensitivity[J].The Journal of Neuroscience,2009.13898-13908.
  • 6李秀华,程焱,杨丽.免疫吸附法治疗重症肌无力的研究进展[J].中国现代神经疾病杂志,2007,7(5):458-460. 被引量:7
  • 7华玲,王利力,刘玉桢,宋静.大剂量免疫球蛋白静脉注射治疗重症肌无力的疗效观察[J].中国现代神经疾病杂志,2006,6(2):148-150. 被引量:4
  • 8Poulas K,Tsouloufis T,Tzartos SJ. Treatment of passively transferred experimental autoimmune myasthenia gravis using papain[J].Clinical and Experimental Immunology,2000.363-368.doi:10.1046/j.1365-2249.2000.01202.x.
  • 9Levinson AI,Wheatley LM. The thymus and the pathogenesis of myasthenia gravis[J].Clinical Immunology and Immunopathology,1996.1-5.doi:10.1006/clin.1996.0001.
  • 10Chen PM,Yen ML,Liu KJ. Immunomodulatory properties of human adult and fetal multipotent mesenchymal stem cells[J].Journal of Biomedical Science,2011.49.doi:10.1186/1423-0127-18-49.

二级参考文献38

  • 1杨丽,程焱.全血灌流吸附治疗重症肌无力的实验研究[J].中华急诊医学杂志,2004,13(10):670-672. 被引量:7
  • 2[1]许贤豪,主编.神经免疫学.武汉:湖北科学技术出版社,2001.119-120.
  • 3[1]Pinching AJ,Peters DK.Remission of myasthenia gravis following plasma-exchange.Lancet,1976,2:1373-1376.
  • 4[2]Ptak J.Changes of plasma proteins after immunoadsorption using lgAdsopak columns in patients with myasthenia gravis.Transfus Apher Sci,2004,30:125-129.
  • 5[3]Ptak J,Lochman J.Immunoadsorption therapy and complement activation.Transfus Apher Sci,2005,32:263-267.
  • 6[4]Takamori M,Ide Y.Specific removal of anti-acetylcholine receptor antibodies in patients with myasthenia gravis.Transfus Sci,1996,17:445-453.
  • 7[5]Takamori M,Maruta T.Immunoadsorption in myasthenia gravis based on specific ligands mimicking the immunogenic sites of the acetylcholine receptor.Ther Apher,2001,5:340-350.
  • 8[6]Nakaji S,Hayashi N.Adsorption column for myasthenia gravis treatment:Medisorba MG-50.Ther Apher Dial,2003,7:78-84.
  • 9[7]Psaridi-Linardaki L,Trakas N,Mamalaki A,et al.Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor alpha-subunit:development of an antigen-specific therapeutic strategy.J Neuroimmunol,2005,159:183-191.
  • 10[8]Psaridi-Linardaki L,Mamalaki A,Tzartos SJ.Future therapeutic strategies in autoimmune myasthenia gravis.Ann NY Acad Sci,2003,998:539-548.

共引文献9

同被引文献33

  • 1杨丽,程焱.全血灌流吸附治疗重症肌无力的实验研究[J].中华急诊医学杂志,2004,13(10):670-672. 被引量:7
  • 2Martinez C, Henao A, Rodriguez JE, et al. Monitoring steady flow effects on cell distribution in engineered valve tissues by magnetic resonance imaging[ J ]. Mol Imaging,2013,12 (7) : 1-13.
  • 3Petrou P, Argov A, Lennon VA, et al. Rare combination of myasthenia and motor neuronopathy, responsive to Msc-Ntf stem cell therapy [ J ]. Muscle Nerve,2014,49(3 ) :455-457.
  • 4Ben-Ami E, Miller A, Ben-ih-Aknin S. T cells from autoimmune pa- tients display reduced sensitivity to immunoregulation by mesenchy- mal stem ceils : role of IL-2 [ J ]. Autoimmun Rev, 2014,13 (2) : 187- 196.
  • 5Farah MH, Olson JM,Sucic HB et al. Generation of neurons by tran- sient expression of neural bHLH proteins in mammalian ceils[ J]. De- velopment, 2010,127 ( 4 ) : 693-697.
  • 6Whitfield MJ, Lee WC, Van Vliet KJ. Onset of heterogeneity in cul- ture-expanded bone marrow stromal ceils [ J ]. Stem Cell Res, 2013, 11 (3) : 1365-1377.
  • 7Pang Y,Li Z,Li Z. GRP78 secreted by tumor ceils stimulates differ- entiation of bone marrow mesenchymal stem cells tocancer-associated fibroblasts[ J]. Biochem Biophys Res Commun,2013,440(4) :558- 563.
  • 8Sampson S, Botto-van Bemden A, Aufiero D. Autologous bone marrow concentrate : review and application of a novel intra-articular orthobio- logic for cartilage disease[J]. Phys Sportsmed,2013,41 (3) :7-18.
  • 9Liu R, Yang Y, Yan X, et al. Abnormalities in eytokine secretion from mesenchymal stem cells in psoriatic skin lesions[ J ]. Eur J Dermatol, 2013,23 (5) :600-607.
  • 10Martinez C, Henao A, Rodriguez JE, et al. Monitoring steady flow effects on cell distribution in engineered valve tissues by magnetic resonance imaging[ J]. Mol Imaging,2013,12 (7) : 1-13.

引证文献6

二级引证文献10

;
使用帮助 返回顶部